Company logo

FGEN - FibroGen, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Francisco, United States
Type: Equity

FGEN price evolution
FGEN
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $120.91 $152.59 $188.55 $135.82
Short term investments $130.43 $183.13 $167.4 $266.31
Net receivables $31.69 $25.6 $17.65 $16.3
Inventory $40.7 $41.18 $42.46 $40.44
Total current assets $364.11 $411.36 $430.55 $492.83
Long term investments $6.61 $8.18 $7.96 $11.48
Property, plant & equipment $85.76 $91.23 $95.37 $100.93
Goodwill & intangible assets
Total noncurrent assets $96.32 $103.77 $108 $117.26
Total investments $137.03 $191.31 $175.35 $277.79
Total assets $460.43 $515.13 $538.54 $610.09
Current liabilities
Accounts payable $19.22 $12.8 $71.28 $30.76
Deferred revenue $161.53 $172.91 $179.58 $198.46
Short long term debt $11.88 $11.01 $9.93 $10.29
Total current liabilities $209.41 $194.07 $254.75 $273.56
Long term debt $190.81 $193.62 $125.25 $17.05
Total noncurrent liabilities $366.21 $381.36 $312.68 $338
Total debt $202.69 $204.63 $135.18 $139.22
Total liabilities $575.63 $575.43 $567.43 $631.53
Shareholders' equity
Retained earnings -$1785.69 -$1722.07 -$1634.39 -$1557.69
Other shareholder equity -$6.92 -$6.25 -$4.57 -$5.72
Total shareholder equity -$157.17 -$102.27 -$68.82 -$21.45
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $135.82 $171.22 $678.39 $126.27
Short term investments $266.31 $233.97 $8.14 $407.49
Net receivables $16.3 $17.4 $41.88 $28.45
Inventory $40.44 $31.02 $16.53 $6.89
Total current assets $492.83 $474.06 $755.11 $702.49
Long term investments $11.48 $173.69 $5.04 $63.19
Property, plant & equipment $100.93 $120.15 $63.25 $82.34
Goodwill & intangible assets
Total noncurrent assets $117.26 $299.76 $71.73 $154.91
Total investments $277.79 $407.66 $13.19 $470.68
Total assets $610.09 $773.82 $826.84 $857.4
Current liabilities
Accounts payable $30.76 $26.1 $24.79 $6.09
Deferred revenue $198.46 $202.66 $145.02 $99.94
Short long term debt $10.29 $10.96 $12.33 $12.35
Total current liabilities $273.56 $225.5 $163.19 $102.75
Long term debt $17.05 $88.78 $25.39 $38.75
Total noncurrent liabilities $338 $319.21 $222.2 $219.25
Total debt $139.22 $99.73 $37.72 $51.1
Total liabilities $631.53 $544.71 $385.39 $321.99
Shareholders' equity
Retained earnings -$1557.69 -$1264.03 -$974.01 -$784.72
Other shareholder equity -$5.72 -$4.16 -$4.5 -$0.75
Total shareholder equity -$21.45 $209.15 $422.18 $516.13
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $40.13 $44.32 $36.16 $34.37
Cost of revenue $4.24 $5.71 $3.49 $4.92
Gross Profit $35.89 $38.61 $32.67 $29.44
Operating activities
Research & development $61.19 $95.48 $74.49 $61.63
Selling, general & administrative $25.57 $31.18 $34.27 $33.97
Total operating expenses $99.37 $126.66 $108.76 $95.59
Operating income -$63.48 -$88.05 -$76.09 -$66.15
Income from continuing operations
EBIT -$58.51 -$84.85 -$74.26 -$64.95
Income tax expense $0.08 -$0.23 $0.07 $0.11
Interest expense $5.02 $3.07 $2.37 $1.12
Net income
Net income -$63.62 -$87.68 -$76.7 -$66.17
Income (for common shares) -$63.62 -$87.68 -$76.7 -$66.17
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $140.73 $235.31 $176.32 $256.58
Cost of revenue $20.28 $12.87 $8.87 $1.15
Gross Profit $120.45 $222.44 $167.45 $255.43
Operating activities
Research & development $296.79 $387.04 $252.92 $209.26
Selling, general & administrative $124.69 $123.92 $106.41 $135.48
Total operating expenses $421.48 $510.97 $359.33 $344.74
Operating income -$301.02 -$288.53 -$191.88 -$89.31
Income from continuing operations
EBIT -$291.86 -$288.6 -$186.53 -$73.77
Income tax expense $0.36 $0.35 $0.36 $0.33
Interest expense $1.44 $1.07 $2.4 $2.88
Net income
Net income -$293.65 -$290.02 -$189.29 -$76.97
Income (for common shares) -$293.65 -$290.02 -$189.29 -$76.97
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$63.62 -$87.68 -$76.7 -$66.17
Operating activities
Depreciation $2.38 $2.71 $2.96 $2.69
Business acquisitions & disposals $0.66
Stock-based compensation $9.48 $15.88 $16.11 $16.22
Total cash flows from operations -$84.54 -$110.57 -$101.59 -$52.51
Investing activities
Capital expenditures -$0.68 -$0.99 -$0.59 -$0.34
Investments $54.9 -$13.95 $104.07 $1.43
Total cash flows from investing $54.22 -$14.29 $103.48 $1.09
Financing activities
Dividends paid
Sale and purchase of stock $20.44 $31.66 $1.2
Net borrowings -$0.02 $71.1 -$0.17 $48.08
Total cash flows from financing -$0.02 $91.53 $31.48 $48.67
Effect of exchange rate -$1.33 -$2.64 -$0.53 $2.49
Change in cash and equivalents -$31.67 -$35.97 $32.85 -$0.26
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$293.65 -$290.02 -$189.29 -$76.97
Operating activities
Depreciation $10.6 $14.81 $22.05 $21.45
Business acquisitions & disposals -$35 -$25 -$2.83
Stock-based compensation $65.6 $71.16 $72.72 $66.27
Total cash flows from operations -$145.93 -$82.23 $81.6 -$78.7
Investing activities
Capital expenditures -$3.73 -$5.19 -$3.99 -$5.75
Investments $127.85 -$396.79 $459.31 $125.77
Total cash flows from investing $89.12 -$426.97 $452.49 $120.02
Financing activities
Dividends paid
Sale and purchase of stock $4.18 $12.7 $37.83 $20.78
Net borrowings $47.76 -$5.89 -$13.02 -$12.33
Total cash flows from financing $46.78 -$0.56 $13.34 -$4.3
Effect of exchange rate -$5.48 $2.6 $4.7 -$0.01
Change in cash and equivalents -$15.52 -$507.17 $552.13 $37.01
Fundamentals
Market cap $181.93M
Enterprise value $263.71M
Shares outstanding 98.34M
Revenue $154.98M
EBITDA -$271.82M
EBIT -$282.56M
Net Income -$294.18M
Revenue Q/Q 155.06%
Revenue Y/Y 26.09%
P/E ratio -0.62
EV/Sales 1.70
EV/EBITDA -0.97
EV/EBIT -0.93
P/S ratio 1.17
P/B ratio -1.21
Book/Share -1.53
Cash/Share 1.23
EPS -$2.99
ROA -55.40%
ROE 336.48%
Debt/Equity -29.45
Net debt/EBITDA -1.67
Current ratio 1.74
Quick ratio 1.54